|
Could I have a statement, please? https://physio-logical.net/baclofentreatmentcom-7559.pdf#pest sarunpharma.com ** PROSENSA, $7.93, down 67 pct (1:17 p.m. ET) An experimental drug for Duchenne muscular dystrophy fromGlaxoSmithKline and Prosensa failed to meet its goal in alate-stage clinical trial, the companies said on Friday. Thedrug, drisapersen, did not show a statistically significantimprovement in the distance that patients could walk in sixminutes compared to a placebo in the Phase three test.
|